ArticleDose-response : a publication of International Hormesis Society
Integrating Network Pharmacology and Experimental Validation Reveals EGFR/PI3K/Akt Axis Mediates Ibrutinib-Induced Cardiotoxicity.
Article in Dose-response : a publication of International Hormesis Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to systematically explore the molecular mechanism underlying ibrutinib-induced cardiotoxicity. Methods: Network toxicology was applied using DrugBank, PharmMapper, GeneCards, OMIM, and TTD databases to identify overlapping targets between ibrutinib and myocardial injury, followed by PPI network construction (STRING; confidence ≥0.7) and GO/KEGG enrichment analyses (Metascape). Molecular docking (AutoDock Vina) verified ibrutinib's binding affinity to core targets. In vitro, H9C2 cardiomyocytes were exposed to ibrutinib (0, 10, 20, 40, and 80 μM) for 24 h; CCK-8, DCFH-DA, EdU, and Calcein-AM/PI assays were performed to assess cell viability, ROS levels, proliferation, and cell death, respectively. Western blot analyzed phosphorylation of EGFR/PI3K/Akt/mTOR pathway proteins. Results: A total of 42 overlapping targets were screened from 337 ibrutinib-related targets and 471 myocardial injury-related genes. PPI network analysis identified EGFR, AKT1, SRC, ESR1, and CASP3 as hub genes, and KEGG enrichment analysis identified the PI3K-Akt pathway as the most significantly enriched cascade. Molecular docking confirmed that ibrutinib stably bound BTK and EGFR with a binding energy of -30.2 kcal/mol and formed multiple hydrogen bonds and salt bridges (2.2-3.2 Å). In H9C2 cells, ibrutinib dose-dependently reduced viability (IC50 = 119.49 μM), increased ROS production (40 and 80 μM), inhibited proliferation (10 and 20 μM), and promoted cell death (5 and 10 μM). Western blot confirmed that ibrutinib significantly downregulated phosphorylation of PI3K p85, Akt (Ser473), mTOR (Ser2448), and p70S6K (Thr389) without altering total protein expression. Conclusion: Ibrutinib induces cardiotoxicity by targeting BTK/EGFR and inhibiting the downstream EGFR/PI3K/Akt/mTOR pathway, providing a mechanistic framework for clinical safety management of BTK inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.